Nature, 2015
One interesting possibility is that -glutamyl can be complexed to extracellular available free cyst(e)ine, imported into the cell and as such can serve as a substrate for GS during GSH synthesis (bypassing GCL reaction)
As innovators change their product lifecycle management approach towards increased patient centricity, transitioning from intravenous (IV) infusion to SC administration with an injection device can be a huge game-changer (patient focus, compliance, differentiation from competitors), with notable examples being Herceptin (trastuzumab, Roche/Genentech), MabThera (rituximab, Roche/Genentech), Actemra (tocilizumab, Roche/Genentech), Benlysta (belimumab, GSK), Entyvio (vedolizumab, Takeda) and others
van Assema DME, Lubberink M, Boellaard R, Schuit RC, Windhorst AD, Scheltens P, et al